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Abstract
Background: Efflux pump activity has been associated with multidrug resistance phenotypes in
bacteria, compromising the effectiveness of antimicrobial therapy. The development of methods for
the early detection and quantification of drug transport across the bacterial cell wall is a tool
essential to understand and overcome this type of drug resistance mechanism. This approach was
developed to study the transport of the efflux pump substrate ethidium bromide (EtBr) across the
cell envelope of Escherichia coli K-12 and derivatives, differing in the expression of their efflux
systems.
Results: EtBr transport across the cell envelope of E. coli K-12 and derivatives was analysed by a
semi-automated fluorometric method. Accumulation and efflux of EtBr was studied under limiting
energy supply (absence of glucose and low temperature) and in the presence and absence of the
efflux pump inhibitor, chlorpromazine. The bulk fluorescence variations were also observed by
single-cell flow cytometry analysis, revealing that once inside the cells, leakage of EtBr does not
occur and that efflux is mediated by active transport. The importance of AcrAB-TolC, the main
efflux system of E. coli, in the extrusion of EtBr was evidenced by comparing strains with different
levels of AcrAB expression. An experimental model was developed to describe the transport
kinetics in the three strains. The model integrates passive entry (influx) and active efflux of EtBr,
and discriminates different degrees of efflux between the studied strains that vary in the activity of
their efflux systems, as evident from the calculated efflux rates:   = 0.0173 ± 0.0057
min-1;   = 0.0106 ± 0.0033 min-1; and   = 0.0230 ± 0.0075 min-1.
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Conclusion: The combined use of a semi-automated fluorometric method and an experimental
model allowed quantifying EtBr transport in E. coli strains that differ in their overall efflux activity.
This methodology can be used for the early detection of differences in the drug efflux capacity in
bacteria accounting for antibiotic resistance, as well as for expedite screening of new drug efflux
inhibitors libraries and transport studies across the bacterial cell wall.
Background
Efflux pumps are major defensive components of the bac-
terial cell wall that actively extrude noxious compounds
from the periplasm and/or cytoplasm, thereby decreasing
their intracellular concentration [1,2]. Active efflux of
antibiotics by bacteria was first described in 1978 in
Escherichia coli resistant to tetracycline [3] and, since then,
it has been proven that the constitutive or inductive
expression of these systems is responsible for the intrinsic
and acquired resistance of many bacterial species to anti-
microbials [4,5]. Bacterial efflux pumps may be divided
into five categories, according to their bioenergetics and
structural characteristics: the ATP-Binding Cassette (ABC)
superfamily, the Major Facilitator Superfamily (MFS), the
Resistance Nodulation cell Division (RND) family, the
Small Multidrug Resistance (SMR) family and the Multid-
rug And Toxic compound Extrusion (MATE) family [5-7].
Efflux pumps may be specific for one substrate or recog-
nize a wide range of structurally dissimilar and unrelated
compounds, including several classes of antibiotics [7,8].
In E. coli, the most common commensal Gram-negative
bacterium of the human gut, at least nine proton depend-
ent efflux pumps responsible for multidrug resistant
(MDR) phenotypes have been described [2,9-11]. Among
these, the tripartite AcrAB-TolC system is recognized as the
most important multi-component efflux system and is
composed of: (i) AcrB, an inner membrane protein that
functions as the transporter component of the pump; (ii)
TolC, the protein that traverses the cell envelope and pro-
vides a conduit to the exterior; and (iii) AcrA, two peri-
plasmic embedded membrane proteins that anchor TolC
to the plasma membrane [12]. The AcrAB-TolC system is
responsible for the extrusion of substrates from the peri-
plasm and/or the cytoplasm. The over-expression of this
efflux system is a major cause of the MDR phenotype of
clinical isolates, due to its ability to extrude several classes
of antibiotics [2,10,13]. Although AcrAB-TolC is consid-
ered the most important efflux system of E. coli, other tri-
partite efflux pumps, such as the AcrEF-TolC can extrude
similar substrates albeit at lower efficiency levels. Moreo-
ver, these pumps can be over-expressed when AcrAB is
deleted or inactivated [8,11,13,14].
Several methods have been used to detect and quantify
the activity of bacterial efflux pump systems using radio-
labeled, metal-labeled or fluorescent substrates to moni-
tor their efflux in bacterial cells [15-21]. Bulk measure-
ment techniques that use fluorescence spectroscopy yield
a general understanding that represents the balance
between entry and extrusion of a given substrate, which
may result from the efflux activities of one or several
pumps [17,19], and where cell membrane permeability
also plays an important role [11,14]. Because the permea-
bility to the substrate may be regulated by a decreased
number of porins or by an increase of the lipopolysaccha-
ride layer of the cell envelope [11,14], the demonstration
of efflux activity invariably involves the use of an agent
that promotes a significant increase of substrate accumu-
lated [19,22,23]. Unless the demonstration of the role of
a specific efflux pump is readily made, i.e. by the quantifi-
cation of the expression level of a specific transporter
[11,13], or by the use of mutants whose specific efflux
pump has been deleted or inactivated [10], very little can
be said about the role that any efflux pump system may
play in the MDR phenotype of bacteria.
Recently, a semi-automated fluorometric method has
been developed by us for the assessment of efflux pump
activity in bulk bacterial cells [22]. The method uses the
common efflux pump substrate ethidium bromide (EtBr)
that has been shown to be a particularly suitable probe for
these studies. In fact it emits weak fluorescence in aqueous
solution (external to the cell) and becomes strongly fluo-
rescent when its concentration within the periplasm
exceeds that of the aqueous solution due to its binding to
cellular components [16]. Such binding must be of a weak
type if the agent is to serve as a useful probe for efflux,
since later intercalation into DNA results in strong bind-
ing that precludes any dissociation of the substrate for
efflux [16,17]. This method can distinguish accumulation,
which reflects the balance between influx and efflux, from
efflux itself [22] and, therefore, has the potential for the
study of the kinetics of EtBr transport. The method was
developed using the wild-type E. coli K-12 AG100 as the
bacterial model and the accumulation and efflux of EtBr
was monitored by real-time fluorometry using the Rotor-
Gene™ 3000 from Corbett Research (Sydney, Australia)
[22-24]. The major innovation of this method is the
simultaneous evaluation of efflux pump activity in vivo
and on-line of a large number of samples, with the possi-
bility to expose the same cell preparation to different envi-
ronmental conditions in a single assay.Journal of Biological Engineering 2009, 3:18 http://www.jbioleng.org/content/3/1/18
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In the study to be described herein, this method has been
used to define and parameterize a mechanistic experimen-
tal model that demonstrates the kinetics of EtBr influx and
efflux by E. coli strains that differ in their capacity to
extrude this molecule. The determination of the influx
and efflux rates (k+ and k-, respectively) of a fluorescent
substrate by the approach proposed allows the quantifica-
tion of the cell overall efflux capacity. This information
can be useful to interpret different phenotypes resulting
from this efflux activity, including multidrug resistance in
clinical bacterial strains.
Methods
Bacteria
The following bacteria were employed in this study: E. coli
K-12 AG100 wild-type strain (argE3 thi-l rpsL xyl mtl (gal-
uvrB) supE44), containing a fully functional AcrAB-TolC
efflux pump system; E. coli AG100A (acrAB::Tn903 Kanr)
with the AcrAB-TolC efflux pump system inactivated due
to the insertion of the transposon Tn903 in the acrAB
operon [10]; and E. coli AG100TET, a AG100 progeny
strain, induced to high level of resistance to tetracycline
(able to survive in 10 g/ml of tetracycline, with an MIC
of 12 g/ml), as previously described, and over-expressing
several efflux pumps, among which acrAB shows the high-
est expression level when exposed to high levels of tetra-
cycline [11,13]. E. coli K-12 AG100 and AG100A have
been previously characterized and were kindly offered by
Hiroshi Nikaido (University of California, Berkeley, Cali-
fornia, USA) [10]. Bacterial cultures were grown in Luria-
Bertani (LB) medium at 37°C with agitation (220 rpm).
Cultures of AG100A and AG100TET were supplemented
with 100 g/ml of kanamycin and 10 g/ml of tetracy-
cline, respectively.
Reagents
Phosphate Buffered Solution (PBS), glucose, EtBr, kan-
amycin, ciprofloxacin, ofloxacin, chloramphenicol, eryth-
romycin, tetracycline and chlorpromazine (CPZ) were
purchased from Sigma-Aldrich Química SA (Madrid,
Spain). EtBr solutions were stored at 4°C and protected
from light. Tetracycline stock solution was prepared in
methanol, whereas kanamycin, ciprofloxacin, ofloxacin,
erythromycin and CPZ were prepared in distilled water
and filtered with 0.22 m syringe filters (Millipore Corpo-
ration, Bedford, USA). Chloramphenicol stock solution
was prepared in ethanol. All working solutions were pre-
pared in distilled water on the day of the experiment. LB
medium was purchased from Difco (Detroit, Michigan,
USA). Mueller-Hinton (MH) broth medium was pur-
chased from Oxoid (Basingstoke, Hampshire, UK).
Determination of minimum inhibitory concentrations 
(MICs)
The MICs for EtBr, the efflux pump inhibitor (EPI) CPZ,
kanamycin, ciprofloxacin, ofloxacin, chloramphenicol,
erythromycin and tetracycline were determined by the
broth microdilution method in 96-well microtitre plates
according to the CLSI guidelines [25]. Briefly, bacterial
strains were incubated overnight in 5 ml of MH broth at
37°C with shaking at 220 rpm. Bacterial cultures were
then diluted in PBS to a McFarland 0.5 turbidity standard.
Aliquots of 0.05 ml were transferred to each well of the
96-well plate that contained 0.15 ml of each compound at
concentrations prepared at 2-fold serial dilutions in MH
broth medium. The plates were incubated at 37°C and the
MIC results registered after 16-18 h. The MIC was defined
as the lowest concentration of compound for which no
growth was observed. In order to assure that the EPI did
not compromise the cellular viability, the concentrations
used in the following work did not exceed 1/2 of the MIC.
The MIC for tetracycline was also calculated in the pres-
ence of CPZ at 1/2 of the MIC.
The semi-automated fluorometric method
The method was carried out using the real-time thermocy-
cler Rotor-Gene™ 3000 (Corbett Research, Sidney, Aus-
tralia) to monitor the accumulation and extrusion of EtBr
on a real-time basis [22,23]. The instrument allows the
selection of the excitation and emission wavelengths that
for EtBr are 530 nm band-pass and 585 nm high-pass fil-
ters, respectively. The fluorescence was acquired in cycles
of 60 seconds, during the desired time interval, at the
required temperature (37°C or 25°C). An explanatory
diagram is provided in Figure 1.
(i) Accumulation assay
The accumulation of EtBr was carried out as previously
described [22]. Briefly, the E. coli strains were grown in 10
ml of LB medium until they reached a mid-log phase,
which corresponded to an optical density at 600 nm
(OD600) of 0.6. The bacteria were then centrifuged at
16,060 ×g for 3 minutes, the pellet washed twice with the
same volume of PBS and the OD600 of the cellular suspen-
sion adjusted to 0.3. Glucose was added to the cellular
suspension to a final concentration of 0.4% (v/v) and
aliquots of 0.095 ml were transferred to 0.2 ml micro-
tubes. EtBr was added in aliquots of 0.005 ml to obtain
final concentrations that ranged from 1.0 to 6.0 g/ml for
E. coli K-12 AG100 and AG100TET and from 0.125 to 1.5
g/ml for AG100A. The fluorescence was monitored in
the Rotor-Gene™ 3000 at 37°C under the conditions
described above. The effect of CPZ in the accumulation of
EtBr was determined under conditions that optimize
efflux (presence of glucose and incubation at 37°C). CPZ
was used at concentrations that did not exceed 1/2 theJournal of Biological Engineering 2009, 3:18 http://www.jbioleng.org/content/3/1/18
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MIC and the fluorescence was measured over a period of
60 minutes.
(ii) Efflux assay
The assessment of the efflux of EtBr was conducted as pre-
viously described [22]. Briefly, the E. coli strains were
loaded with EtBr under conditions that favor accumula-
tion (no glucose, 25°C and presence of CPZ). When the
maximum level of EtBr accumulation was reached
(approximately 60 minutes), the bacteria were centrifuged
(16,060 ×g for 3 minutes) and the medium was replaced
by: i) PBS without glucose; ii) PBS containing glucose; and
iii) PBS without glucose and with CPZ (control of mini-
mum efflux). Aliquots of 0.1 ml were transferred to 0.2 ml
microtubes and the assay was performed at 37°C with
continuous measurement of fluorescence as described
above. The efflux of EtBr is presented in terms of relative
fluorescence, which is obtained from the comparison
between the fluorescence observed for the bacteria in the
presence or absence of glucose and the control in which
the cells are exposed to conditions of minimum efflux
(i.e., absence of glucose and presence of CPZ). Each exper-
iment was conducted in triplicate and the results obtained
did not vary.
Model to quantify EtBr efflux in E. coli
(i) Quantification of intracellular EtBr concentration
In order to assess the amount of EtBr extruded from the
cells, one has to quantify the amount retained inside the
cells. First, a calibration curve is determined that correlates
the initial fluorescence of the buffer containing EtBr (FLo)
with the corresponding EtBr concentration (varying from
0 to 6 g/ml): [EtBr]intial = 0.1201 × FL0 + 0.0373(R =
0.99). Then, for each concentration tested, an EtBr accu-
mulation assay was performed, as described above. To
quantify the intracellular EtBr concentration, at the end of
the accumulation assay, 0.6 ml of each EtBr containing
buffer were separated from the cells by centrifugation at
16,060 ×g  for 10 minutes and the supernatant filtered
with 0.22 m syringe filters from Millipore Corporation
Experimental flowchart of the semi-automated fluorometric method Figure 1
Experimental flowchart of the semi-automated fluorometric method.
Semi-automated fluorometric method
E. coli culture (OD600 = 0.6)
Accumulation assay Step #4: Efflux assay
Step #1: Cells centrifuged and resuspended in
PBS to OD600 = 0.3. Add glucose and EtBr:
AG100 and AG100TET: [EtBr] = 1 – 6 μg/mL
AG100A: [EtBr] = 0.125 – 1.5 μg/mL
Aquisition of fluorescence (530/585 nm
excitation/detection) at 37ºC
Step #2: Selection of [EtBr] to be
tested with the EPI (in this case, CPZ)
Add CPZ and the selected [EtBr] to bacteria
in the presence/absence of glucose
Step #3: Selection of [CPZ] that
causes maximum accumulation
Conditions that cause maximum EtBr
accumulation: [EtBr] selected in #2; [CPZ] 
selected in #3; incubate at 25ºC for 60 min.
Centrifuge and resuspend in a 
EtBr-free buffer
Add glucose (0.4%) and CPZ
Step #5: Analysis of CPZ effect on
EtBr efflux Aquisition of fluorescence (530/585 nm
excitation/detection) at 37ºC
Aquisition of fluorescence (530/585 nm
excitation/detection) at 37ºCJournal of Biological Engineering 2009, 3:18 http://www.jbioleng.org/content/3/1/18
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(Bedford, USA). The fluorescence of the cell free buffer
was measured in the Rotor-Gene™ 3000 (FL(PBS+EtBr)filt
non corrected).
Since some EtBr is retained by the filter itself, a correction
factor must be used to account for this difference. Thus,
the corrected fluorescence of the filtered buffer corre-
sponds to (FL(PBS+EtBr)filt corrected). = 1.2289 ×
(FL(PBS+EtBr)filt non corrected). + 0.7032 (R = 0.99). The dif-
ference between the initial fluorescence of the EtBr con-
taining buffer (FLo) and (FL(PBS+EtBr)filt corrected gives the
fluorescence corresponding to the intracellular EtBr con-
centration. However, the fluorescence data from the trans-
port assays measured experimentally still contains a
component from the EtBr that remains in solution. Thus,
each value of the experimental accumulation curve can
then be corrected by subtracting the background corre-
sponding to the fluorescence of the initial EtBr concentra-
tion, originating FLint exp corr. By plotting the previously
determined EtBr intracellular concentration for the final
value of FLint exp corr, for each initial EtBr concentration
tested, a new relation is achieved: [EtBr]int = 0.022 × FLint
exp corr+ 0.06 (R = 0.99), which allows the conversion of
the experimental fluorescence data over time into intrac-
ellular EtBr concentration over time. The correlations
shown here were determined for the wild-type E. coli K-12
AG100. Similar relations were determined specifically for
the other two strains used (AG100A and AG100TET).
(ii) Mathematical and statistical analyses
The model was fitted to the experimental values ([EtBr]int
vs t) using the software Table Curve™ 2D from Jandel Sci-
entific - AISN Software STATISTICA, which allowed the
determination of the values of the parameters describing
the influx and efflux rates, k+ and k-, respectively. Three
independent assays were conducted and the results shown
are the average ± standard deviation. P-value from the
ANOVA statistical test was calculated.
(iii) Model validation
The predictive model proposed was validated by compar-
ing the experimental data obtained using E. coli K-12
AG100, AG100A and AG100TET cell suspensions incu-
bated in the presence of different concentrations of EtBr
and the curves generated by the model, using the k+ and k-
constants determined as described above.
Flow cytometry
This methodology was used to corroborate the analysis of
the data obtained with the semi-automated fluorometric
method. Therefore, the samples from the accumulation
and efflux assays, used in the semi-automated fluoromet-
ric method, were also analyzed by flow cytometry, in
order to compare the results obtained with these two
methodologies. Data acquisition and analysis were per-
formed using a FACSCalibur™ (BD Biosciences, San Jose,
CA, USA). EtBr was excited at 488 nm and the fluores-
cence detected through a 585 nm filter (FL-2 channel).
(i) Accumulation assay
E. coli strains were cultured in 10 ml of LB medium at
37°C and 220 rpm until an OD600 of 0.6. Aliquots of 1.0
ml were centrifuged at 16,060 ×g for 3 minutes, the super-
natant discarded and the pellet washed twice with PBS.
The OD600 of the bacterial suspension was adjusted to 0.3
using PBS without glucose. EtBr was added at a final con-
centration of 1 g/ml and CPZ was added to a final con-
centration of 20 g/ml. Following incubation at 25°C for
60 minutes, aliquots of 0.5 ml were taken for fluorescence
measurement in the flow cytometer FACSCalibur™. Data
was collected for at least 10,000 events per sample.
(ii) Efflux assay
After loading the bacteria with EtBr (1 g/ml) in the pres-
ence of CPZ (20 g/ml), the bacterial suspension was cen-
trifuged at 16,060 ×g for 3 minutes. The supernatant was
removed and the pellet resuspended in EtBr-free PBS,
adjusting the OD600 to 0.3. Efflux was assessed in the pres-
ence and absence of glucose at 0.4% (v/v). Aliquots of 0.5
ml were taken after 2.5, 5, 15, 30 and 60 minutes after
incubation at 37°C, for fluorescence measurement in the
flow cytometer FACSCalibur™. Analyses were performed
with an acquisition of at least 10,000 events per sample.
Results and Discussion
Detecting EtBr efflux mediated by E. coli efflux pump 
systems
Experiments were carried out with EtBr concentrations
that did not affect in any way the cell viability, i.e., that did
not exceed 1/2 the MIC for EtBr (Table 1). In this case and
as previously demonstrated, accumulation of EtBr and its
extrusion from E. coli are the result of the balance between
EtBr entry by passive diffusion (influx) and the extrusion
activity of efflux pump systems, primarily the AcrAB-TolC
[11,13]. As shown by Figure 2, the accumulation of EtBr
under conditions that are considered to maximize efflux,
i.e., presence of glucose and 37°C, begins to take place at
a concentration of EtBr that exceeds 1.0 g/ml for the
wild-type E. coli K-12 AG100 (Figure 2A), 0.250 g/ml for
the AG100A (acrAB inactivated; Figure 2B), and 1.0 g/ml
for the AG100TET(acrAB  and other efflux pump genes
over-expressed; Figure 2C). As expected, the strain that
over-express efflux systems (AG100TET) accumulates the
least amount of EtBr even when the maximum concentra-
tion of EtBr to which it is exposed is 6 g/ml. On the con-
trary, the AG100A, whose AcrAB efflux pump has been
inactivated, accumulates approximately 25 times more
EtBr when exposed to a far lower concentration of 1.5 g/
ml of EtBr. The importance of the AcrAB-TolC efflux sys-
tem is further illustrated by the comparison of accumula-Journal of Biological Engineering 2009, 3:18 http://www.jbioleng.org/content/3/1/18
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tion of EtBr by the wild-type AG100 to that by the
AG100A, when both strains are exposed to 1 g/ml of
EtBr.
Accumulation of EtBr inside the bacterial cells can be
increased in the presence of an EPI such as phenothiazines
(e.g. CPZ), compounds that have been shown to inhibit
efflux activity of Gram-negative bacteria [4,5,22]. Thus,
these compounds are usually employed for the demon-
stration of over-expressed efflux pumps of bacteria
[5,19,22,23]. Because of the real-time capacity and sensi-
tivity of the semi-automated fluorometric method, the
demonstration of the effects of an EPI, such as CPZ, on the
intrinsic efflux system of the wild-type E. coli K-12 AG100
is readily made. As shown by Figure 3A (A1 and A2), high
concentrations of CPZ maximize the amount of EtBr accu-
mulated only when glucose is absent from the medium.
Similar results were obtained for the strains AG100TET and
AG100A (data not shown). The effect of CPZ on the accu-
mulation of EtBr by wild-type E. coli K-12 AG100 is simi-
larly demonstrated and confirmed with the aid of flow
cytometry (Figure 3B).
The on-line visualization of efflux activity by the EtBr
loaded cells requires that accumulation of EtBr has previ-
ously taken place. Therefore, before performing the efflux
assays, bacteria are exposed to conditions that promote
significant accumulation of EtBr [22,23]. To this extent,
we have chosen a temperature of 25°C, absence of glucose
and presence of CPZ (20 g/ml), to promote maximum
accumulation, within 60 minutes. When maximum accu-
mulation has taken place under these conditions, the bac-
teria are washed free of EtBr and CPZ, and resuspended in
fresh buffer with and without glucose. Fluorescence read-
ings were conducted over a period of 15 minutes at 37°C.
As shown by Figure 4, restoration of optimum conditions
of glucose, noted to prevent accumulation, are required
for the extrusion of EtBr. This assay shows that E. coli cells
need an energy source for efflux to take place.
Therefore, this methodological approach proved its use-
fulness for the demonstration of active efflux of EtBr in E.
coli and the strategy developed allowed to differentiate
influx (passive diffusion into the cell) from efflux activity
(active efflux through pumps).
Modeling EtBr transport across E. coli cell wall
In order to quantify the efflux activity, a mechanistic
experimental model that establishes a balance related to
the intracellular EtBr concentration was developed, as
described below:
where [EtBr]int is the intracellular EtBr concentration (g/
ml); [EtBr]ext is the external EtBr concentration (g/ml); k+
is the rate of EtBr entry into the cells (min-1) and k- corre-
sponds to the rate of EtBr efflux from the cells (min-1).
Therefore,
where [EtBr]Tot is the total EtBr concentration (g/ml).
Replacing equation (1.2) in equation (1.1) and solving it
for [EtBr]int, it is possible to obtain the following equa-
tion, which describes the EtBr transport across the cell
wall of E. coli:
The equation developed herein (eq. 1.3) allied to the tech-
nical approach used to quantify the intracellular EtBr con-
centration (Methods) allowed us to quantify the degree of
EtBr efflux activity in the three E. coli strains (AG100,
AG100A and AG100TET). This strategy is based on the dis-
tinct levels of EtBr fluorescence in solution and inside the
cells. EtBr emits fluorescence when it is free in solution (in
this case, PBS) in a concentration dependent manner,
accurately captured by the photomultiplier detector with
the 585 nm high-pass filter of the Rotor-Gene™ 3000 that
differentiates g/ml differences [22,24]. The high sensitiv-
ity of this detector ensue the definition of a calibration
curve, which correlates fluorescence (FL0) and the initial
dE t B rint
dt
kE t B r kE t B r
ext int
[]
= [] − []
+− (1.1)
EtBr EtBr EtBr
Tot ext [] = [] + [] int (1.2)
EtBr (t)
k
kk
EtBr EtBr (t 0)
k
kk
EtBr
int Tot int [] =
+
++ − [] + []=−
+
++ − [] T Tot
(k k )t e
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
−+
+−
(1.3)
Table 1: MIC values of EtBr and several antibiotics for E. coli AG100, AG100A and AG100TET.
MIC (g/ml)
E. coli strains EtBr KAN CIP OFX CHL ERY TET TET + CPZ
AG100 150 15 0.03 0.12 8 100 2.0 0.5
AG100A 5 > 200 0.004 0.015 2 6.25 0.5 0.5
AG100TET 300 10 0.12 0.48 > 16 100 12 3
Ethidium Bromide (EtBr); Kanamycin (KAN); Ciprofloxacin (CIP); Ofloxacin (OFX); Chloramphenicol (CHL); Erythromycin (ERY); Tetracycline 
(TET); and Chlorpromazine (CPZ). Kanamycin was included as control for the presence of Tn903 in E. coli AG100A (acrAB::Tn903 Kanr). The 
tetracycline MICs were also calculated in the presence of 30 g/ml (AG100), 10 g/ml (AG100A) and 70 g/ml (AG100TET) of CPZ (1/2 CPZ MIC).Journal of Biological Engineering 2009, 3:18 http://www.jbioleng.org/content/3/1/18
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EtBr concentration in solution, before the cells are added
to the medium, varying from 0 g/ml to 6 g/ml [24]:
where [EtBr]initial = [EtBr]Total. When the E. coli cells are
exposed to EtBr containing buffer (1 to 6 g/ml for AG100
and AG100TET; 0.125 to 1.5 g/ml for AG100A), the cells
start to accumulate EtBr that enters by passive diffusion,
with the efflux pump systems trying to balance this entry
according to the kinetics presented in Figure 2. At these
low concentrations, EtBr does not reach the cellular com-
ponents in the cytoplasm to which it could bind irrevers-
ibly, being effluxed from the cytoplasm and periplasm by
either single- or multi-component efflux systems [26,27].
When the concentration of EtBr within the periplasmic
space exceeds significantly its extrusion, EtBr is translo-
cated beyond the inner plasma membrane where the
medial sites of the cell contain nucleic acids to which the
EtBr can intercalate almost irreversibly, after which extru-
sion is not possible [16,17,26,27].
EtBr 0.1201 FL 0.0373(R 0.99)
ini 0 [] =× + =
Accumulation of EtBr at increasing concentrations by E. coli K-12 AG100 (A), AG100A (B) and AG100TET (C) Figure 2
Accumulation of EtBr at increasing concentrations by E. coli K-12 AG100 (A), AG100A (B) and AG100TET (C). 
The bacteria were exposed to increasing concentrations of EtBr at 37°C in the presence of glucose. Note: assays for AG100A 
were carried out with lowest EtBr concentrations (0.125 g/ml - 1.5 g/ml) -- see text.
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Using the rationale described in Methods, it is possible to
correlate the fluorescence readings by the semi-automated
fluorometric method in bulk cells to the EtBr concentra-
tion that remains inside the cells; [EtBr]int = 0.022 × FLint
exp corr + 0.06 (R = 0.99). With the assistance of the software
Table Curve™ 2D from Jandel Scientific - AISN Software
STATISTICA, it is then possible to adjust the model (eq.
1.3.) to the experimental data and determine the values of
the constants k+ and k-, which represent a measure of the
rate of entry and the rate of efflux of EtBr into and out of
the cell, respectively (Figure 5). Table 2 summarizes the
values of k+ and k- obtained for the three strains tested. The
values obtained show similar influx rates for the three E.
coli  strains studied, as expected, since this parameter
reflects the entry of EtBr by passive diffusion. Both the
passive influx absolute values and their variation among
the three strains are negligible when compared to the val-
ues obtained for the efflux rates.
The model proposed accurately describes the behavior of
the three strains, showing a lower efflux rate for the
AG100A strain when compared to the wild-type AG100 (P
value = 0.0023), as a result of the inactivation of the
AcrAB-TolC system in the mutant strain. For the AG100TET
strain the model revealed a significantly increased efflux
rate compared to the wild-type strain (P value = 0.0057).
Effect of chlorpromazine (CPZ) on EtBr accumulation by E. coli K-12 AG100 Figure 3
Effect of chlorpromazine (CPZ) on EtBr accumulation by E. coli K-12 AG100. The bacteria were loaded with EtBr at 
1 g/ml in the presence of increasing concentrations of CPZ for a period of 60 minutes at 37°C in the presence and absence of 
glucose and accumulation assessed by: (A1 and A2) the semi-automated fluorometric method; (B) flow cytometry, represented 
by an histogram overlay corresponding to the data selected for analysis (2nd gate) for E. coli K-12 AG100 (i) without EtBr or 
CPZ, (ii) after 60 minutes of exposure to EtBr (1 g/ml) and (iii) after 60 minutes of exposure to EtBr (1 g/ml) and CPZ (20 
g/ml) at 37°C without glucose. Data in graphics A1 and A2 correspond to the same assay and were separated for the sake of 
figure clarity.
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This result reflects the higher efflux activity in this tetracy-
cline adapted strain due to the over-expression of efflux
pumps, particularly of the AcrAB-TolC system [11,13].
Moreover, the results provided by the model, in terms of
EtBr efflux rates, correlate with the MIC for EtBr for each
of the strains studied (Table 1). While the wild-type strain,
E. coli AG100 (MICEtBr = 150 g/ml), showed a EtBr efflux
rate of 
 = 0.0173 ± 0.0057 min-1, the AcrAB deleted strain, E. coli
AG100A (MICEtBr = 5 g/ml), had the lowest EtBr efflux
rate 
kAG100
−
Detection of EtBr efflux in E. coli K-12 AG100 Figure 4
Detection of EtBr efflux in E. coli K-12 AG100. The bacteria were loaded with EtBr at 1 g/ml in the presence of CPZ 
(20 g/ml) for a period of 60 minutes at 25°C. After replacing the buffer with EtBr-free PBS with or without glucose, the efflux 
was assessed by: (A) the semi-automated fluorometric method, performed at 37°C for 15 minutes; and (B) flow cytometry, 
represented by an histogram overlay corresponding to the data selected for analysis (2nd gate) for E. coli K-12 AG100 immedi-
ately after replacing the buffer with EtBr-free PBS (t = 0) and 15 minutes after incubation at 37°C with or without glucose.
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 = 0.0106 ± 0.0033 min-1. Conversely, the tetracycline
induced strain, E. coli AG100TET, over-expressing the
AcrAB system, shows a much higher efflux rate 
 = 0.0230 ± 0.0075 min-1, which corresponds to an MIC
for EtBr of 300 g/ml. MICs of each strain towards several
antibiotics known to be efflux pump substrates also
showed a correlation between efflux activity and resist-
ance level to these drugs (Table 1). The determination of
the MICs for tetracycline in the presence of the EPI CPZ
reinforced the role played by efflux on such resistance, as
the MICs values decreased in the presence of sub-inhibi-
tory concentrations of this EPI, according to the efflux
activity previously determined for each strain (Table 1).
kAG A 100
−
kAG TET 100
−
Table 2: Influx (k+) and efflux (k-) rates for E. coli K-12 AG100, 
AG100A and AG100TET.
E. coli strains k+ (min-1)k - (min-1)
AG100 0.0019 ± 0.0009 0.0173 ± 0.0057
AG100A 0.0035 ± 0.0012 0.0106 ± 0.0033
AG100TET 0.0025 ± 0.0009 0.0230 ± 0.0075
k+ and k- were determined using the software Table Curve™ 2D from 
Jandel Scientific - AISN Software STATISTICA to adjust the model 
(eq. 1.3.) to the experimental data obtained with the semi-automated 
fluorometric method (Figure 2). The results represent an average of 
three independent assays with the correspondent standard deviation.
Influx (k+) and efflux (k-) rates of EtBr in the E. coli strains tested Figure 5
Influx (k+) and efflux (k-) rates of EtBr in the E. coli strains tested. The values shown represent averages of three inde-
pendent experiments and respective standard deviations for the three E. coli strains tested: AG100, AG100A and AG100TET.
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This approach allowed us, for the first time in the litera-
ture, to calculate the values of EtBr influx/efflux rates (k+
and k-) for E. coli and to construct a predictive model for
the accumulation curve of this molecule at any concentra-
tion by a given E. coli strain, provided that EtBr concentra-
tion does not affect the cellular viability. An example of
such calculation is provided in Figure 6, for three different
concentrations of EtBr for the E. coli strains used. When
these predictive curves are compared to the experimental
data a close fit is obtained (Figure 6), thus validating the
proposed model.
Conclusion
In this work we have applied the technical advantages of
the semi-automated fluorometric method [22] for the
development and application of an experimental model
to describe and quantify the efflux pump activity in E. coli.
The semi-automated fluorometric method affords the in
vivo and on-line evaluation of the efflux pump activity by
real-time fluorometry using the Rotor-Gene™ 3000, and
represents an innovative technique when compared to
other technologies [23]. Based upon the differences of flu-
orescence that reflect differences on the EtBr concentra-
tions outside and inside the cells, the technique provides
Examples of model fitting to experimental data Figure 6
Examples of model fitting to experimental data. The figures represent the fitting of the model to the experimental data 
for the time course of intracellular EtBr concentration in E. coli strains AG100, AG100A and AG100TET, incubated in the pres-
ence of different EtBr concentrations. In each case, the solid line represents the model fit.
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a powerful tool for the real-time monitoring of efflux
kinetics in bacterial cells. Moreover, it has potential for the
identification of new efflux pump substrates, as well as
new bacterial EPIs [23]. A more fundamental application
is the extension of this methodology to understand the
transport kinetics of EtBr or other fluorescent substrates in
bacterial cells.
We used such approach to differentiate and quantify EtBr
transport in E. coli, and an experimental model was devel-
oped which parameterizes passive entry (influx) and
active efflux of EtBr. The methodology developed allowed
to detect differences in the EtBr efflux activity among
strains that differ in their efflux pump expression, high-
lighting the importance of these systems in the extrusion
from the cell of toxic compounds such as EtBr [6,7,10].
Although the experimental model presented was designed
based upon a set of three canonic, isogenic strains, as a
way to assess the method's sensitivity to differentiate their
singular efflux activities, it can be applied to other E. coli
strains or bacteria, since it is based on the overall transport
of EtBr across the bacterial cell wall, which is common
among bacteria [2,7,16,22,23]. It should be stressed how-
ever that it allows measuring the overall efflux activity
rather than efflux related to a specific pump. For evalua-
tion of the role played by a pump, a mutant specific for
that pump must be used. The determination of influx and
efflux rates for each of the strains to be analyzed opens
new insights and opportunities for exploration of cell wall
permeability, as well as for the control of the efflux activity
in bacterial cells, representing a quantitative method to
determine efflux activity. This approach may be used to
elaborate a standardized data base for different reference
strains relative to efflux activity (efflux rates), providing
the means by which one can evaluate the resistance due to
efflux pump activity in standardized conditions between
laboratories. It represents a particularly suitable procedure
for the assessment of efflux pump activity in MDR clinical
isolates and screening for potential inhibitors of such
activity. Such approaches may contribute to a better
understanding of the bacterial efflux systems as a resist-
ance mechanism and to design new therapeutic strategies
against MDR bacterial infections [28].
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